BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Public ClinicalTrials.gov record NCT06917079. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
Study identification
- NCT ID
- NCT06917079
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Industry
- Enrollment
- 387 participants
Conditions and interventions
Conditions
- Advanced Lung Carcinoma
- CRC (Colorectal Cancer)
- KRAS G12A
- KRAS G12C
- KRAS G12D
- KRAS G12S
- KRAS G12V
- Metastatic Colorectal Cancer (CRC)
- Metastatic Non-Small Lung Cell Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
- NSCLC
- Non-Small Cell Lung Cancer
- PDAC - Pancreatic Ductal Adenocarcinoma
- Solid Tumor, Adult
Interventions
- BBO-11818 Drug
- Cetuximab Drug
- FOLFOX Drug
- Gemcitabine Drug
- NALIRIFOX Drug
- Nab-paclitaxel Drug
- Pembrolizumab Drug
- Pemetrexed Drug
- Platinum chemotherapy (cisplatin or carboplatin) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2025
- Primary completion
- Jul 31, 2027
- Completion
- Aug 31, 2029
- Last update posted
- Mar 22, 2026
2025 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute - West Los Angeles Office | Los Angeles | California | 90025 | Recruiting |
| University of California San Diego Moores Cancer Center | San Diego | California | 92037 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| NYU Langone Health | New York | New York | 10016 | Recruiting |
| Columbia University Irving Medical Center | New York | New York | 10032 | Recruiting |
| Sarah Cannon Research Institute at Mary Crowley | Dallas | Texas | 75230 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Recruiting |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06917079, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06917079 live on ClinicalTrials.gov.